{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.7","upperLimit":"30.5","value":"22.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"DOR is defined as the time from date of the first documented CR/nCR or PR to the date of the first documented progression or relapse or death due to MM","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.","id":"OG000","title":"LBH589 + Bortezomib + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"FAS: The FAS comprised of all subjects who took at least one dose of any study treatment component.","reportingStatus":"POSTED","timeFrame":"duration of study up to approx. 4 years","title":"Duration of Response (DOR) Per Investigator","type":"SECONDARY","unitOfMeasure":"months"}